This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ICAD To Highlight Xoft System To Treat Skin, Breast And Gynecological Cancers At ASTRO

Stocks in this article: ICAD

ASTRO Booth Number 2449-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that its Xoft subsidiary will be showcasing its Xoft ® Axxent ® Electronic Brachytherapy System ® at the American Society for Radiation Oncology’s (ASTRO) 55 th Annual Meeting being held from September 22-25, 2013 in Atlanta at booth #2449. The Xoft System can be used to treat non-melanoma skin cancer (NMSC), early-stage breast cancer with Intraoperative Radiation Therapy (IORT) and Accelerated Partial Breast Irradiation (APBI), vaginal, endometrial and cervical cancer.

“This year’s activities at ASTRO demonstrate iCAD’s commitment to delivering targeted, innovative and cost-effective radiation therapy solutions to radiation oncologists to help them to more effectively treat a variety of cancers,” said Ken Ferry, President and CEO of iCAD. “It’s an exciting time for iCAD with new product introductions, significant progress in our post-market breast cancer study, and the presentation of longer term clinical data that supports the increased momentum of our NMSC application.”

The Company’s technology will be featured in the following educational sessions and at the Company’s booth:

Industry-Expert Theater

Topic: “Electronic Brachytherapy Utilizing the Xoft ® System for the Treatment of Non-Melanoma Skin Cancer”
Presentation: Monday, September 23 from 10:15 to 10:45 a.m.
Presenter: Ajay Bhatnagar, MD, MBA, Cancer Treatment Services Arizona, Affiliate of 21 st Century Oncology, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine and DermEbx
Location: Rear of 100 Aisle, Exhibit Hall B1

New Data on the Use of the Xoft System for Non-Melanoma Skin Cancer (NMSC)

Topic: “Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results at Three Years,” which presents new clinical data assessing adverse effects, cosmesis and recurrence rates related to high dose rate (HDR) electronic brachytherapy for the treatment of NMSC with the Xoft System.
Presentation: Tuesday, September 24 at 2:10 p.m.
Presenter: Dr. Bhatnagar

Scientific Session S in Room B405


Breast IORT Post-market Study Update

Topic: “A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer,” providing discussion of the ongoing study, which has 19 participating centers and more than 150 patients treated and which continues to enroll patients and enlist centers.
Presentation: Throughout Exhibit Hall hours
Location: iCAD Exhibit Booth 2449


Radiation oncologists, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants and practice administrators comprise ASTRO’s nearly 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals, cancer treatment centers and academic research facilities around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. Together, these teams, treat more than 1 million cancer patients each year.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs